The biologics market size is expected to grow around $320
billion by 2021 growing at double digit compound annual growth rate (CAGR). The
growth in the biologics market is mainly due to government initiatives for the
research and development of biopharmaceutical drugs, increasing healthcare
access among developing and underdeveloped nations, and rising mergers and
acquisitions in the biologics market.
Major trends witnessed in the biologics market over the
historic period include increasing demand for biologics in the treatment of
complex diseases, rising development of next generation biologics and revised
FDA regulations facilitating biologics drug development.
Download Sample
Report On Biologics Market At
The major
mergers and acquisition in market has helped the big pharma companies to
overcome the obstacles in R&D productivity. As a result, currently the
pipelines of major companies like AstraZeneca, Sanofi have biological drugs,
constituting nearly 30-40%, in the clinical stage.
ADMA Biologics, Inc. acquired
Therapy Business of Biotest Pharmaceuticals Corporation, a 50% minus one share
of ADMA. The deal includes two U.S. Food and Drug Administration (FDA) licensed
products, Nabi-HB (Hepatitis B Immune Globulin, Human) and BIVIGAM (Immune
Globulin Intravenous, Human), manufacturing and testing operations with two
facilities in Boca Raton, Florida. ADMA also received $27.5 million in cash of
which $15.0 million is in the form of a loan from Biotest Pharmaceuticals
Corporation.
Order Biologics Market Report At
About The Business
Research Company
The Business Research Company is a Business Intelligence
Company which excels in company, market and consumer research. It has offices
in the UK, the US and India and a network of trained researchers in 15
countries globally.
Contact Information.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on Linkedin: https://in.linkedin.com/company/the-business-research-company
